J
Jiwei Liu
Researcher at Dalian Medical University
Publications - 34
Citations - 5103
Jiwei Liu is an academic researcher from Dalian Medical University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 8 publications receiving 4328 citations.
Papers
More filters
Journal ArticleDOI
Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis
TL;DR: Wang et al. as mentioned in this paper evaluated the efficacy and safety of lenvatinib as second-line therapy in Chinese patients with unresectable hepatocellular carcinoma (HCC).
Journal ArticleDOI
Histone deacetylase 4 inhibition ameliorates the social deficits induced by Ephrin-B2 mutation
Peijun Ju,Jianhua Chen,Le Ma,Ying Cheng,Jiwei Liu,Ying Sun,Cuizhen Zhu,Zhe Shen,Wei Wang,Yanmin Peng,Usman Ali,Nanjie Xu,Jinghong Chen +12 more
TL;DR: In this paper , the synaptic protein Ephrin-B2 (EB2) plays an important role in the maintenance and reconfiguration of inhibitory synapses in the medial prefrontal cortex (mPFC).
Journal ArticleDOI
Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.
Lu Si,Zhengyun Zou,Weizheng Zhang,Meiyu Fang,Xiaoshi Zhang,Zhiguo Luo,Jing Chen,Gang Huang,Peng Zhang,Ying Chen,Jiwei Liu,Ji-Yan Liu,Junping Zhang,Di Wu,Yu Chen,Xiaoting Wei,Peng Sun,Zhongwei Jia,Jun Guo +18 more
TL;DR: In this article , tunlametinib was well tolerated and demonstrated encouraging treatment response rate in patients with NRAS-mutant melanoma, even for those immunotherapy failed.
Journal ArticleDOI
Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study
Lu Si,Xiaoshi Zhang,Yongqian Shu,Hongming Pan,Di Wu,Jiwei Liu,Lili Mao,Xuan-Ming Wang,Xi Zhi Wen,Yanhong Gu,Lingjun Zhu,Shijie Lan,Xinfeng Cai,Scott J. Diede,Hai-Ming Dai,Cuizhen Niu,Jianfeng Li,Jun Guo +17 more
TL;DR: Second-line pembrolizumab was well tolerated and had clinically meaningful antitumor activity in Chinese patients with advanced melanoma and subgroup analysis suggested particular benefit in PD-L1–positive and BRAF wild-type acral melanoma, although small subgroup sizes preclude definitive conclusions.